Clinical Trial Modernization Act

The Clinical Trial Modernization Act was introduced in the Senate on April 29, 2026, by Senator Tim Scott (R-SC) with one cosponsor, and referred to the Committee on Finance. It is in the earliest legislative stage. The bill authorizes the Secretary of HHS to issue grants and contracts for community education, outreach, and recruitment activities aimed at increasing clinical trial enrollment among underrepresented populations. However, the authorization of appropriations is for 'such sums as may be necessary' for fiscal years 2027 and 2028 — no specific dollar amount is provided. This means actual funding requires a separate appropriations bill, which is uncertain at this stage. The money trail is weak: authorization without appropriation provides no guaranteed spending. The mechanism is grant-based, not direct procurement or tax credits. Potential beneficiaries include clinical research organizations (CROs) that offer patient recruitment and decentralized trial services, such as IQVIA ($IQV), ICON ($ICLR), and Syneos Health. However, without a funding level, the revenue impact is speculative. No real market data was provided for these tickers, so no price trend analysis is possible. The competitive landscape for CROs is mature, with these three firms dominating the market. The bill's focus on community-based and multilingual outreach could favor CROs with existing decentralized trial capabilities, but the lack of funding specifics limits conviction. The legislative timeline is long: the bill must pass committee, be voted on by the Senate, pass the House, and be signed into law. Even then, appropriations are needed. This is a multi-year process with low probability of near-term market impact.